Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023;21(1):10-12.
doi: 10.2174/1570159X20666220425133824.

Classical Hallucinogens As Antidepressant Drugs: A Cautionary Approach

Affiliations
Editorial

Classical Hallucinogens As Antidepressant Drugs: A Cautionary Approach

Rafael G Dos Santos et al. Curr Neuropharmacol. 2023.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

References

    1. Dos Santos R.G., Hallak J.E.C. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neurosci. Biobehav. Rev. 2020;108:423–434. doi: 10.1016/j.neubiorev.2019.12.001. - DOI - PubMed
    1. Gasser P., Holstein D., Michel Y., Doblin R., Yazar-Klosinski B., Passie T., Brenneisen R. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J. Nerv. Ment. Dis. 2014;202(7):513–520. doi: 10.1097/NMD.0000000000000113. - DOI - PMC - PubMed
    1. Grob C.S., Danforth A.L., Chopra G.S., Hagerty M., McKay C.R., Halberstadt A.L., Greer G.R. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry. 2011;68(1):71–78. doi: 10.1001/archgenpsychiatry.2010.116. - DOI - PubMed
    1. Griffiths R.R., Johnson M.W., Carducci M.A., Umbricht A., Richards W.A., Richards B.D., Cosimano M.P., Klinedinst M.A. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 2016;30(12):1181–1197. doi: 10.1177/0269881116675513. - DOI - PMC - PubMed
    1. Ross S., Bossis A., Guss J., Agin-Liebes G., Malone T., Cohen B., Mennenga S.E., Belser A., Kalliontzi K., Babb J., Su Z., Corby P., Schmidt B.L. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J. Psychopharmacol. 2016;30(12):1165–1180. doi: 10.1177/0269881116675512. - DOI - PMC - PubMed

Publication types

MeSH terms